PMC3461627_01
Right axillary node biopsy demonstrating diffuse large B-cell lymphoma.
CRIM.ONCMED2012-685919.001.jpg
PMC3461627_01_CRIM.ONCMED2012-685919.001.jpg
fig1
She underwent excisional biopsy of a right axillary node which demonstrated DLBCL (Figure 1).
Right breast ductal carcinoma in situ.
CRIM.ONCMED2012-685919.002.jpg
PMC3461627_01_CRIM.ONCMED2012-685919.002.jpg
fig2
Ultrasound-guided needle core biopsy of the breast lesions demonstrated ductal carcinoma in situ (DCIS) in the right breast (Figure 2), and estrogen and progesterone receptor positive, HER2 receptor negative infiltrating ductal carcinoma in the left breast (Figure 3).
Left breast infiltrating ductal carcinoma.
CRIM.ONCMED2012-685919.003.jpg
PMC3461627_01_CRIM.ONCMED2012-685919.003.jpg
fig3
Ultrasound-guided needle core biopsy of the breast lesions demonstrated ductal carcinoma in situ (DCIS) in the right breast (Figure 2), and estrogen and progesterone receptor positive, HER2 receptor negative infiltrating ductal carcinoma in the left breast (Figure 3).
Dose volume histogram showing coverage of breast tumor bed (red) with standard breast tangents and incidental ipsilateral axillary coverage (purple).
CRIM.ONCMED2012-685919.004.jpg
PMC3461627_01_CRIM.ONCMED2012-685919.004.jpg
fig4
Completion of her breast conservation therapy with standard breast tangent fields allowed for incidental inclusion of levels I and II of the axilla in the treatment field with 88% of the right axilla receiving 3,000 cGy or more (Figure 4).